PHASE-II STUDY OF INTRAVENOUS IDARUBICIN IN UNFAVORABLE NON-HODGKINS-LYMPHOMA

Idarubicin, a new analogue of daunorubicin, was administered i.v. at a dose of 15 mg/m2 to 31 previously treated patients with unfavorable non-Hodgkin's lymphoma. Clinical characteristics included median age, 69 years; performance status, 1, and prior chemotherapeutic regimens, 1. Twenty of the...

Full description

Saved in:
Bibliographic Details
Published in:Cancer research (Chicago, Ill.) Ill.), 1992-07, Vol.52 (14), p.3871-3874
Main Authors: CASE, DC, GERBER, MC, GAMS, RA, CRAWFORD, J, VOTAW, ML, HIGANO, CS, PRUITT, BT, GOULD, J
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Agranulocytosis - chemically induced
Antineoplastic agents
Biological and medical sciences
Chemotherapy
Drug Administration Schedule
Drug Evaluation
Female
Heart Diseases - chemically induced
Humans
Idarubicin - adverse effects
Idarubicin - therapeutic use
Infusions, Intravenous
Life Sciences & Biomedicine
Lymphoma, Non-Hodgkin - drug therapy
Male
Medical sciences
Middle Aged
Oncology
Pharmacology. Drug treatments
Science & Technology
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Idarubicin, a new analogue of daunorubicin, was administered i.v. at a dose of 15 mg/m2 to 31 previously treated patients with unfavorable non-Hodgkin's lymphoma. Clinical characteristics included median age, 69 years; performance status, 1, and prior chemotherapeutic regimens, 1. Twenty of the patients were relapsing after prior therapy and 11 were refractory; 29 had received prior anthracycline or anthracenedione. Responses were observed in 43% of patient (3 complete remission and 10 partial remission) with a median duration of 10+ months (2-29+ months). Idarubicin was well tolerated with nonhematological toxicities (nausea/vomiting, mucositis, and anorexia) seen in
ISSN:0008-5472
1538-7445